New certifying board to credential healthcare workers in AI

The newly incorporated American Board of Artificial Intelligence in Medicine (ABAIM) is soon to begin credentialing healthcare workers in AI, machine learning and deep learning.

The group announced its intentions March 9, noting that it was only recently incorporated as a not-for-profit entity.

ABAIM’s main activity will be awarding board certification to individuals who pass an exam demonstrating a firm grasp of advanced concepts related to AI and its iterations used in healthcare.  

The certification also will validate the ability of those so certified to analyze the benefits and pitfalls of these technologies in real-world scenarios.

The ABAIM says its ultimate goal is to “enable healthcare professionals to participate in development, assessment, selection and implementation of AI, machine learning and deep learning tools for their benefit and that of the institutions they serve today and in the future.”

Two physicians are serving as the board’s chairs and driving the initiative: Orest Boyko, MD, PhD, a psychology research professor at the University of Southern California; and Anthony Chang, MD, of the Sharon Disney Lund Medical Intelligence and Innovation Institute (MI3) at Children’s Hospital of Orange County in California.

Artificial Intelligence and its related technologies are “increasingly important to healthcare as a whole,” Boyko said.

Chang added that ABAIM has a modular curriculum that will enable a wide range of healthcare professionals—as well as patients, data scientists and IT personnel—to become knowledgeable in the application of AI, ML and DL tools and technologies.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.